Abstract
Dual anti-platelet therapy is critical in preventing recurrent ischemic events in acute coronary syndrome (ACS) to prevent early stent thrombosis after percutaneous coronary intervention (PCI) [1,2]. Ticagrelor is a new P2Y12-receptor antagonist which overcomes most of the limitations of clopidogrel with a faster onset of action and a more intense and consistent platelet reactivity (PR) inhibition [3]. Accordingly, in the PLATO trial, ticagrelor was superior to clopidogrel in decreasing major adverse cardiac events (MACE) in the setting of ACS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
